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To assess whether calmodulin (CaM) could have a role in the behavioral sensitization induced by repeated intermittent amphetamine. 
CaM content was determined in several brain areas from rats repeatedly administered saline or amphetamine. Rats were treated with am- 
phetamine using an escalating dose paradigm and withdrawn for either 4 weeks (withdrawn group) or 30 min (non-withdrawn group). CaM 
content was measured in cytosol and 100,000 x g membrane fractions from striatum, limbic forebrain. medial prefrontal cortex. hippocam- 
pus and cerebellum. In the withdrawn group, CaM was significantly increased in both striatal membranes and cytosol and in the mesolimbic 
membranes from amphetamine-treated rats. There were no changes in CaM in the medial prefrontal cortex, hippocampus or cerebellum. In 
the non-withdrawn group, there was no significant change in CaM in striatal or mesolimbic fractions but CaM was significantly decreased in 
cytosol of the medial prefrontal cortex and hippocampus as compared to saline controls. This decrease could be related to the tolerance that 
has developed to the amphetamine after the repeated treatments. In the withdrawn group, challenge with a low dose of amphetamine (I 
mg/kg) elicited a translocation of CaM from membranes to cytosol in the striatum and limbic forebrain of rats repeatedly treated with am- 
phetamine, but not in saline-treated rats. Our findings that the change in CaM occurs in striatum and limbic forebrain, requires time after 
treatment to develop and exhibits persistence after withdrawal correlate with known characteristics of behavioral sensitization to amphet- 
amine. These results suggest that CaM could contribute to neurochemical events underlying behavioral sensitization to amphetamine. 
INTRODUCTION 
Repeated use of amphetamine (AMPH) in humans 
can lead to a psychotic state that clinically resembles 
paranoid schizophrenia4*‘.“. AMPH-induced psychosis 
disappears upon withdrawal from the drug or after treat- 
ment with dopamine (DA) receptor blocking drugs. Ad- 
dicts will retain increased sensitivity to the drug for years 
after withdrawal from the drug3s. Behavioral sensitiza- 
tion after repeated intermittent AMPH can be demon- 
strated in animals. The behavioral sensitization in ani- 
mals is characterized by a more rapid onset of 
stereotyped behavior and more intense stereotyped 
movements than in controls and a marked increase in 
AMPH-induced rotational behavior (for review, see ref. 
33). The behavioral effects develop with time after with- 
drawal from repeated intermittent AMPH treatment and 
will persist for up to a year’*. Thus AMPH-induced be- 
havioral sensitization in animals may be due to long-term 
neural adaptations in areas of brain responsible for the 
psychomotor or psychotogenic effects of AMPH. Con- 
siderable evidence suggests that AMPH-induced stereo- 
typed behavior and AMPH-induced locomotor behavior 
are considered due to increased DA release in the cau- 
date putamen and nucleus accumbens, respec- 
tively3.17*26. Similarly, the activation of DA systems is 
necessary for the development of sensitization. Admin- 
istration of DA receptor antagonists, particularly DA D , 
receptor antagonists, with AMPH blocks the develop- 
ment of behavioral sensitization’,22+4’1. Several studies 
have demonstrated that behavioral sensitization to 
AMPH is accompanied by an enhanced ability of DA to 
be released by stimuli, e.g. AMPH, Kf or electrical 
stimulation”,34,41. The increased releasability of DA dis- 
plays many of the characteristics of behavioral sensitiza- 
tion such as persistence and development upon with- 
drawa13’.“‘. 
We have investigated changes in the endogenous Ca*+- 
binding protein, calmodulin (CaM), in rat striatum fol- 
lowing repeated treatment with AMPH. CaM modulates 
the effect of Ca*+ on cyclic nucleotide metabolism and 
protein phosphorylation-dephosphorylation, and alters 
calcium transport and cytoskeletal interactions24. Calm- 
odulin is particularly enriched in synaptic fractions of the 
- 
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bra in  1° and  is i nvo lved  in synthesis  and  re lease  o f  trans-  
mi t te rs  6'23'24. Pha rmaco log i ca l  t r e a t m e n t s  that  r egu la te  
d o p a m i n e r g i c  act ivi ty  resul t  in changes  in C a M  in sub- 
ce l lu lar  f rac t ions  o f  s t r i a tum s'13. 
In  p rev ious  s tudies  we  found  tha t  C a M  is inc reased  in 
rat  s t r i a tum u p o n  wi thdrawa l  f r o m  r e p e a t e d  t r e a t m e n t  
wi th  A M P H  31'37. In  addi t ion ,  we found  that  a cha l lenge  
with  a low dose  o f  A M P H  will elicit  a t rans loca t ion  o f  
C a M  f r o m  m e m b r a n e s  to  cytosol  in s t r ia tum f r o m  rats 
that  w e r e  r e p e a t e d l y  t r ea t ed  wi th  A M P H  but  no t  sa- 
l ine 37. This  t r ans loca t ion  d id  no t  occur  in rats  no t  sensi- 
t ized to A M P H .  T h e  i n v o l v e m e n t  o f  C a M  in so m a n y  
neura l  funct ions  suggests  that  it cou ld  play a role  in 
A M P H - i n d u c e d  behav io ra l  sensi t izat ion.  To fu r ther  ex- 
p lo re  a ro le  for  C a M  in behav io ra l  sensi t izat ion,  we  mea-  
sured  C a M  in m e m b r a n e  and  cytosol  f ract ions  of  severa l  
rat  b ra in  a reas  a f te r  r e p e a t e d  in t e rmi t t en t  A M P H .  T h e s e  
s tudies  w e r e  c o n d u c t e d  in one  g roup  of  rats  that  were  
wi thd rawn  4 w e e k s  f r o m  the  r e p e a t e d  A M P H  t r e a t m e n t  
and in a n o t h e r  g roup  that  was no t  w i thd rawn  fo l lowing 
A M P H  t r ea tmen t .  We  found  that  C a M  was se lec t ively  
inc reased  in s t r i a tum and  meso l imb ic  a reas  af ter  with-  
drawal  f r o m  r e p e a t e d  A M P H .  O n  the  o t h e r  hand ,  C a M  
e i the r  s h o w e d  no  change  o r  was d e c r e a s e d  in severa l  
b ra in  a reas  in the  n o n - w i t h d r a w n  A M P H  group  as com-  
pa red  to contro ls .  
MATERIALS AND METHODS 
Chronic treatment paradigm 
Female Spragne-Dawley derived rats, 150-200 g (Holtzman Co. 
Inc., Madison, WI) were used in all experiments. Rats were divided 
into two groups; half was injected i.p. with saline (SAL) and the other 
half with escalating doses of AMPH. Animals were housed in groups 
of 6 and injections were given twice a day for 5 days with 10--12 h 
separating the two injections; this was followed by two drug-free days. 
This schedule was repeated for 4 weeks. The rats received a total of 
40 injections (20 injection days) accordin~ to the following schedule: 
injection days 1-3 (1.0 mg/k~); 4-5 (2 mg/kg); 6--7 (3 mg/kg); 8-9 (4 
mg/kg); 10-11 (5 mg/kg); 12-14 (6 mg/kg); 15-17 (7 mg/kg); 18-20 (8 
mg/kg). This escalating dose regimen was S'Lmilar to that of Robinson 
and Camp 3s. The control group received an equivalent number of 
SAL injections. For one experiment, rats were sacrificed 30 rain after 
the last injection on the 20th injection day. This was the non-withdrawn 
group. The withdrawn group was saoificed 28 days after the last in- 
jection. In the withdrawn group, rats received an i.p. challenge injec- 
tion of either 0.9% SAL or 1.0 mg/kg AMPH 30 rain before sacrifice 
such that 4 groups were formed with 5 rats in each group: SAL-SAL 
(SS), SAL-AMPH (SA), AMPH-SAL (AS) and AMPH-AMPH 
(AA). The 4-week treatment with AMPH did not significantly alter 
the growth rate of the rats. Throughout the study the average weight 
of the AMPH-trcated rats was not signitieantly different from the av- 
erage weight of the SAL control groups. 
All animals were sacrificed on the same day and the brain areas 
were dissected on ice, weighed and the tissue frozen in liquid N 2. 
Brain areas were dissected using a brain cutting block as described 
by Heffner et ai. 16. The mesolimbic area (or lirnbie forebrain) con- 
tains both nucleus accumbens and olfactory tubercle. Medial pre- 
frontal cortex was dissected, which was shown to have the highest 
concentration of DA TM. Tissue was stored for no longer than 2 
weeks until assayed for CaM. 
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Measurement of CaM content 
Tissue was prepared for measurement of CaM by homogeniza- 
tion in 40 mM Tris, pH 7.4 at 4 *(2, containing 0.32 M sucrose and 
3 mM MgCI 2. Particulate (membrane) and eytosolic fractions were 
prepared by centrifugation at 100,000 g for 60 min. The particulate 
fraction was resuspended in 40 mM Tris and solubilized with 1% 
Lubrol PX. Homogenate fractions were also treated with 1% Lu- 
brol PX. Samples were frozen in liquid N 2 and stored at -70 °C 
until CaM levels were measured using a radioimmunoassay (RIA) 
(New England Nuclear, Boston, MA). Samples were heated for 6 
min before further dilution into RIA buffer and assay. The anti- 
genicity of CaM increased with time of sample heating so that the 
time of heating was carefully controlled. In some assays, the CaM 
antiserum used was that developed in sheep by Dr. Michael 
Welsh ag. Results were comparable with those of the NEN radioim- 
munoassay kit. Samples from SAL- and AMPH-treated rats within 
any group were always analyzed simultaneously to avoid interassay 
variability. Statistical significance was determined by one way anal- 
ysis of variance (ANOVA) with posttest Bonferroni t-test analysis 
calculated using GraphPad Instat and by a two-tail Students t-test. 
Materials 
AMPH was purchased from The University of Michigan Labo- 
ratory of Animal Medicine. Calmodulin was purified from bovine 
testes by the method of Dedman et al.5. Donkey anti-sheep IgG, 
rabbit serum, rice starch, polyethylene glycol 8000, Tween 20, Tri- 
ton X-100, bovine serum albumin and Lubrol PX were purchased 
from Sigma Chemical Co. (St. Louis, MO). 
RESULTS 
CaM content in brain areas after 4 weeks o f  withdrawal 
f rom repeated intermittent A M P H  
In  these  expe r imen t s ,  we  inves t iga td  bo th  a change  in 
C a M  con ten t  e l ic i ted by r e p e a t e d  A M P H  t r e a t m e n t  and 
TABLE I 
CaM concentration in rat striatum and limbic forebrain after re- 
peated amphetamine treatment: 4 week withdrawal 
Female Sprague-Dawley rats were treated with escalating doses 
of AMPH and given a challenge with 1.0 mg/kg AMPH as de- 
scribed in Roseboom et al.37. Statistical differences were deter- 
mined by ANOVA using the program GraphPad. Striatum: n = 
5; Cytosol, P < 0.001 as determined by ANOVA, * AS is signif- 
icantly different from SS and AA at P < 0.05. Membranes: P < 
0.03 as significantly determined by ANOVA, * AS is different 
from AA at P < 0.05. Limbic forebrain: n = 10; Cytosol, P < 
0.02 as determined by ANOVA, * AA is significantly different 
from SA at P < 0.05. Membranes, P < 0.0002 as determined ~ by 
ANOVA, + AS is significantly different from SS, SA and AA at 
P < 0.01. 
Brain area Treatment 
group 
Total CaM (ng CaM/l~g prot. .+ S.E.M.) 
Cyt Memb 
Striatum SS 0.45 ± 0.04 0.35 -+ 0.05 
SA 0.58 _+ 0.09 0.30 _+ 0.02 
AS 0.72 + 0.09* 0.48 -+ 0.05* 
AA 1.0 ± 0.09* 0.31 -+ 0.04 
Limbic fore- SS 0.62 .+ 0.05 0.36 -+ 0.02 
brain SA 0.63 .+ 0.04 0.34 _+ 0.02 
AS 0.71 .+ 0.06 0.67 -+ 0.08 + 
AA 0.9 -+ 0.08* 0.39 -+ 0.04 + 
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the ability of a challenge injection of acute AMPH to al- 
ter subcellular CaM localization in both SAL and AMPH 
pretreatment groups. In the striatum, there was a signif- 
icant increase in CaM in both the cytosol and membrane 
fractions after treatment with escalating doses of AMPH 
(AMPH-SAL group). This increase was reflected in both 
the concentration of CaM (Table I) and in total CaM 
(Fig. 1A). In striata from both SAL- and AMPH-treated 
groups, there was a nearly equal distribution of CaM in 
membranes and cytosol (Fig. 1A). Challenge with a low 
dose (1 mg/kg) of AMPH, however, elicited a redistri- 
bution of the CaM in the AMPH-treated group, decreas- 
ing the CaM in the membranes and increasing the CaM 
in the cytosol. This redistribution is reflected as a signif- 
icant decrease in the membrane:cytosol (M/C) ratio of 
_ --IA. Striatum T 
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Fig. lA-C. For legend see next caption. 
CaM as shown in Table II. No change in the content or 
distribution of the CaM occurred with AMPH challenge 
in the SAL-treated animals. 
A significant increase in CaM was evident in the mem- 
brane fraction of the mesolimbic area (nucleus accum- 
bens + olfactory tubercle) after repeated AMPH treat- 
ment (Fig. 1B; Table I). In contrast to the striatum, 
there was no change in CaM in the mesolimbic cytosol 
fraction in the AMPH-SAL group. In the mesolimbic 
area, however, just as in the striatum, a challenge dose 
of 1 mg/kg AMPH decreased membrane-bound CaM 
and increased cytosolic CaM in the repeated AMPH- 
treated rats. The WC ratio in the limbic forebrain for 
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Fig. 1. CaM content in cytosol (C) and membrane (M) fractions 
from various rat brain areas after treatment with saline (S) or es- 
calating doses of AMPH (A) and withdrawn 4 weeks. Female 
Sprague-Dawley rats were treated with SAL or escalating doses of 
AMPH and given a challenge dose of SAL or AMPH 30 min be- 
fore sacrifice as described in Materials and Methods. Results are 
given as ng CaM per mg tissue wet weight % S.E.M. Statistical dif- 
ferences were determined by one-way ANOVA using postanalysis 
Bonferroni t-tests. A: striatum: n = 5; cytosol, P < 0.0001 as de- 
termined by ANOVA; AA is different from values for SS and AS 
at P < 0.05, and for SA at P < 0.001. Membranes: P < 0.002 as 
determined by ANOVA; AS is different from SS at P < 0.05 and 
from AA at P < 0.01. B: limbic forebrain: n = 10; cytosol, P < 
0.02 as determined by ANOVA; AA is significantly different from 
AS and SS at P < 0.05. Membranes, P < 0.02 as determined by 
ANOVA, AS is significantly different from SS and AA at P < 0.05. 
C: frontal cortex: n = 5. D: hippocampus: R = 5. E: cerebellum: 
n = 5. 
TABLE II 
Effect o f  A M P H  challenge on the subcellular localization o f  CaM 
after repeated AMPH: 4 weeks withdrawal 
Female Sprague-Dawley rats were treated as described in the 
legend to Fig. 1. Membrane/Cytosol (M/C) ratios were calculated 
from values for total CaM in membrane and cytosol fractions as 
given in Fig. 1A-E. 
Brain area M/C ratio 
SS SA AS A A  
Striatum 1.2+0.1 1.1+0.2 1.1+0.2 0.5+0.06* 
Limbic forebrain 1.3+0.07 1.1+0.1 1.8+0.3 0.8+0.15"* 
Frontal cortex 0.9+0.1 0.97+0.1 1.2+0.1 1.2+0.1 
Hippocampus 0.9+0.08 1.2_+0.1 1.0+0.1 1.3_+0.2 
Cerebellum 0.45_+0.06 0.45_+0.04 0.57_+0.06 0.4_+0.04 
* P < 0.007 as determined by ANOVA, value for AA is signifi- 
cantly less than value for AS, SS or SA at P < 0.05. 
** P < 0.001 as determined by ANOVA, value for AA is signif- 
icantly less than value for AA, SS or SA. 
the A M P H - A M P H  group was significantly less than that  
of  the A M P H - S A L  group (Table II) .  The  challenge dose 
of  A M P H  had no effect on mesol imbic CaM content  or  
distr ibution in the SAL- t rea t ed  group.  
No significant changes in CaM were evident  in e i ther  
membrane  or  cytosol fractions in medial  prefrontal  cor- 
tex, h ippocampus  or  cerebel lum after  r epea ted  A M P H  
t rea tment  (Fig. 1C-E) .  The re -was  no change in CaM 
when the data  were expressed as concentrat ion in ng//zg 
prote in  (da ta  not  shown).  In  addi t ion,  challenge with 1 
mg/kg A M P H  did not  change the subcellular  distr ibution 
of CaM in ei ther  r epea ted  saline- or  A M P H - t r e a t e d  rats 
in these areas (Fig. 1C-E) .  In  all bra in  areas,  CaM was 
TABLE III 
CaM content in rat brain areas after repeated amphetamine treat- 
ment: no withdrawal 
Female Sprague-Dawley rats were treated with escalating doses 
of AMPH or SAL as a control as described in the legend to Ta- 
ble I. Animals were sacrificed 30 min after the last injection so 
that they were not withdrawn from the drug. Statistical differ- 
ences were determined by a two-tail Student's t-test, n = 5. 
Brain area Treatment 
group 
Total CaM (ng/mg wet wt) 
Cytosol Membrane 
Striatum SAL 21.0 -+ 2.8 21.0 -+ 3.7 
AMPH 13.8 -+ 2.4 12 -+ 1.6" 
Limbie forebrain SAL 18 -+ 1 24 -+ 2.7 
AMPH 14 -+ 1.3 18 -+ 1.3 
Frontal cortex SAL 12.8 -+ 1.6 7.8 -+ 1.2 
AMPH 7.4 -+ 1 9.6 -+ 1.2 
Hippocampus SAL 11 -+ 1.4 8.0 -+ 0.4 
AMPH 5.6 -+ 0.7** 9.4 -+ 0.5 
*P < 0.05 as compared to corresponding value for SAL-treated 
rats; **P < 0.01 as compared to corresponding value for SAL- 
treated rats. 
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nearly equal ly dis t r ibuted be tween membrane  and cyto- 
sol fractions except  in the cerebel lum. In cerebel lum,  
approximate ly  70% of  the total  CaM was located in the 
cytosol.  
C a M  con ten t  in var ious  brain  areas o f  rats n o t  w i t h d r a w n  
f r o m  A M P H  t rea tmen t  
To determine  whether  the increase in CaM found in 
s tr iatum and limbic forebrain  developed during treat-  
ment  with A M P H  or  required t ime after  t rea tment ,  a 
group of rats was t rea ted  with the escalating doses of  
A M P H  but sacrificed 30 min after the last injection. The 
results are  shown in Table III .  In contrast  to the results 
from the withdrawn group,  no increase in CaM in ei ther  
membrane  or  cytosol fractions was de tec ted  in s tr iatum 
after repea ted  A M P H  t rea tment  in the non-withdrawn 
group. In fact, there  was a slight decrease  in CaM in the 
striatal fractions from the A M P H - t r e a t e d  rats but  it was 
not  statistically significant. Similarly, there  were no sig- 
nificant changes in CaM in the cytosol or  membrane  
fract.ions in the mesollmbic area.  
Significant decreases in CaM in the cytosol were found 
in the medial  prefrontal  cor tex and the h ippocampus 
from A M P H - t r e a t e d  rats as compared  to controls.  De-  
creases in CaM in the cytosol were not  accounted for by 
increases in the membrane  fractions. 
DISCUSSION 
In non-human animals,  behavioral  sensit ization to 
A M P H  is manifested as an increase in psychomotor  
st imulant  effects of  A M P H  for long per iods  of  t ime fol- 
lowing drug t rea tment  33. Behaviora l  sensit ization in rats 
has several  wel l -documented characterist ics which in- 
clude: (1) deve lopment  with t ime after  a single injection, 
(2) long-lasting effects, (3) requi rement  for intermit tent  
but  not  continuous adminis t ra t ion of  A M P H  and (4) in- 
creased degree of sensit ization with t ime after with- 
drawa132'33. Fur ther ,  male  rats show less robust  sensiti- 
zat ion than females.  Therefore ,  in o rder  for a neuro-  
chemical  effect to be causally re la ted  to behavioral  sen- ... 
sitization, it should d e m o n s t r a t e  similar characteristics.  
A n  enhancement  of releasabil i ty of  D A  has been  dem- 
ons t ra ted  after repea ted  A M P H  t rea tment  and the effect 
correlates with the characterist ics given above 32'33. En- 
hanced release of  D A  has been  demons t ra ted  in stria- 
tum 19"33'34"41 and nucleus accumbens 18'2°'36 after repea ted  
A M P H  t rea tment .  The increase in D A  release can be 
demons t ra ted  using A M P H ,  K + or  electrical  st imula- 
t ion 2. 
Previous studies with agents that  al ter  dopaminergic  
sensitivity such as antipsychotic drugs, 6-hydroxydopa-  
mine and st imulant  drugs,  have suggested a relat ionship 
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between CaM content or localization and dopaminergic 
activity in rat striatumx. We have previously reported 
that repeated AMPH treatment elicited an increase in 
CaM in rat striatum”,37. The increase was evident after 
a 5-day treatment with 3 mg/kg AMPH with lo-day with- 
drawal”’ or a 4-week treatment with escalating doses of 
AMPH”’ as used in this study. We chose the escalating 
dose paradigm in our study because this treatment re- 
duces the amount of individual variation in behavior 
measured after AMPH treatment in comparison with 
other treatments of constant low-dose regimens36. The 
time course of behaviors during treatment and after 
withdrawal as well as neurochemical changes in DA re- 
lease, content and metabolite concentrations are well- 
documented3’. In addition, this type of regimen is most 
likely to be followed by humans taking the drug. 
In this study we found that CaM was increased in 
subcellular fractions in both striatum and limbic fore- 
brain after 4 weeks of withdrawal from an escalating 
dose regimen. A change in both areas would be expected 
if the increase in CaM were related to sensitization since 
both locomotor activity and stereotyped behaviors in- 
duced by AMPH are enhanced after repeated AMPH 
treatment. These behaviors are considered to be due to 
release of DA in the nucleus accumbens and caudate 
nucleus, respectively3.17*26. It is unclear whether dopam- 
inergic systems in other brain areas such as frontal cor- 
tex or hippocampus are altered by the repeated AMPH 
treatment or play a significant role in the sensitization 
process. Robinson et al. 34 found an enhancement in pre- 
frontal cortex DA utilization in ovariectomized female 
rats that had been treated repeatedly with AMPH. There 
was no change in CaM in any of the fractions in the 
frontal cortex, hippocampus or cerebellum. Therefore, 
the principal change in CaM content after withdrawal 
from escalating doses of AMPH was found in areas of 
rat brain that are primarily involved in the behavioral 
sensitization. 
Increases in CaM in rat striatum after chronic AMPH 
treatment have also been reported by Popov et al.30 and 
Popov and Matthies2’. These investigators found in- 
creases in CaM after repeated AMPH were reflected in 
either cytosol or membrane fraction of striatum depend- 
ing upon the dose. They reported an increase in CaM in 
hippocampus but not nucleus accumbens after a 21-day 
treatment with 5 mg/kg AMPH. The differences in our 
results could be due to the fact that (1) they used male 
rats, whereas we used female, and (2) their measure- 
ments were made after only two days of withdrawal or 
(3) a different treatment regimen was used. 
In this study, no significant increase in CaM was ob- 
served in the striatum or mesolimbic areas in AMPH- 
treated rats that were not withdrawn from the drug. Fol- 
lowing the escalating dose regimen, sensitized responses 
to locomotor or stereotyped behavior do not develop 
until two weeks after completion of the escalating dose 
regimen2x. Interestingly, we found a significant decrease 
in CaM in the cytosol fractions from frontal cortex and 
hippocampus after repeated AMPH treatment and a 
trend toward a decrease in striatal fractions. Immedi- 
ately after withdrawal from the escalating dose para- 
digm, rats show tolerance to the psychomotor effects of 
AMPH. The decrease in CaM could likely be related to 
the tolerance that has developed to the drugs. Since 
AMPH was in the rat brains at time of sacrifice, the de- 
crease could be due to an acute effect of the AMPH. In 
preliminary studies we found no change in CaM content 
in striatum 30 min after acute doses of AMPH up to 8 
mg/kg (Gnegy, unpublished studies). The reduction of 
CaM after repeated AMPH seems not to involve a trans- 
location of CaM since a corresponding increase in an- 
other fraction was not found. We have found that the 
CaM antibody obtained both from Dr. Welsh and from 
the RIA kit will measure CaM bound to other proteins. 
Therefore a reduction in detection of CaM due to in- 
creased binding of CaM to CaM-binding proteins cannot 
account for the results. It is possible that AMPH treat- 
ment could alter the turnover of CaM in brains areas. 
We demonstrated previously that a challenge with a 
lower dose of AMPH would alter the localization of 
CaM in striatum from rats treated with escalating doses 
of AMPH37. A low dose of AMPH, 1 mg/kg, had no ef- 
fect on CaM lozalization in striatum from SAL-treated 
rats, but did elicit a membrane-to-cytosol translocation 
of CaM in AMPH-treated rats. Higher doses of AMPH, 
however, have been found to cause a membrane-to-cy- 
tosol translocation of CaM in control, non-AMPH- 
treated rats’“, although Popov and Matthies2” found that 
5 mg/kg AMPH caused a translocation of CaM from cy- 
tosol to membrane in rat striatum. Our results suggest 
that the system responsible for the translocation showed 
greater activity after the repeated AMPH treatment due 
either to enhanced postsynaptic responsiveness or an in- 
creased DA release. Both AMPH” and DA’2,2’ have 
been shown to elicit the translocation of CaM from 
membranes to cytosol using striatal membrane fractions 
or slices. A role for the D,DA receptor in this activity 
was suggested by the fact that CAMP itself could elicit a 
membrane-to-cytosol translocation of CaM in vitro”.12. 
The translocation of CaM from membranes to cytosol 
correlated with a decreased responsiveness of adenylyl 
cyclase to DA2’. Similarly, we found that challenge with 
low-dose AMPH induced a pronounced down-regulation 
of DA-stimulated adenylyl cyclase activity in rats with- 
drawn 2-4 weeks from the escalating dose of AMPH 
regimen”. Thus the AMPH-elicited translocation of 
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CaM has functional consequences for the cell as demon- 
strated by adenylyl cyclase activity and may profoundly 
affect other systems as well. Increasing the concentration 
of CaM in the cytosol could activate cytosolic CaM-de- 
pendent enzymes such as CaM-dependent protein ki- 
nases, CaM-dependent phosphodiesterases or calcineu- 
r in.  
The function of the increase in CaM after withdrawal 
from repeated AMPH is not known but the level of in- 
volvement of CaM in many areas of synaptic function 
suggest that it could play a role in either the increased 
release of DA or heightened postsynaptic responses, or 
both. CaM has been shown to have a role in increasing 
neurotransmitter release 6'23 in particular through phos- 
phorylation of synapsin 1 by CaM-dependent protein ki- 
nase I123"27. Our laboratory has demonstrated that CaM 
can increase the sensitivity and response of striatal ade- 
nylyl cyclase to DA by a potentiative interaction with 
Gs 11'14'15. We found a small yet significant increase in 
DA-stimulated adenylyl cyclase activity 4 weeks after 
withdrawal from treatment with escalating doses of 
A M P H  37 . 
In summary, changes in CaM content in rat brain af- 
ter an escalating dose regimen of AMPH show some 
correlation with characteristics of behavioral sensitiza- 
tion which develop after this treatment. The increase in 
CaM was found in striatum and limbic forebrain, areas 
involved in AMPH-induced stereotyped and locomotor 
behaviors, respectively. Heightened stimulus-induced 
DA release has been measured in these areas 32 in 
AMPH-sensitized rats. The increase in CaM is long-last- 
ing, i.e., it is evident 4 weeks after ceasing the AMPH 
treatments and develops with time after withdrawal from 
the drug. In rats not withdrawn from AMPH, CaM lev- 
els either did not change from controls or were de- 
creased. Therefore changes in CaM could contribute to 
the neurochemical changes underlying sensitized behav- 
iors evident after repeated AMPH treatment. 
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